Multi-peptide Vaccination Uses, Dosage, Side Effects and more
Sponsored by the University Hospital Tuebingen in Germany, Multi-peptide Vaccination is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein. It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)) and aims to induce broad T-cell immunity.
| Attribute | Details |
|---|---|
| Trade Name | Multi-peptide Vaccination |
| Generic | CoVac-1 |
| CoVac-1 Other Names | Multi-peptide vaccination, Multipeptide cocktail |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
